Enrique Grande: Failure of Trials to Enhance Outcomes in mRCC Patients Re-challenged with Immunotherapy
Enrique Grande shared a post on X:
“2 phase 3 trials have failed to improve outcomes re-challenging patients with metastatic renal cell carcinoma to receive immunotherapy.
I’ve got questions now:
1. It also applies to adjuvant-ICI refractory patients?
2. Can we extrapolate the data to metastatic urothelial field?
The jury is out- Toni Choueiri, Petros Grivas, Sumanta K. Pal, Neeraj Agarwal and Axel S. Merseburger.
Nivolumab/Tivozanib Fails to Improve PFS in Advanced RCC After Prior Immune Checkpoint Inhibition.”
Source: Enrique Grande/X
Enrique Grande, MD, PhD, MSc, is the Director of the Medical Oncology Program and Clinical Research lead at MD Anderson Cancer Center Madrid. Dr. Grande specializes in researching genitourinary and endocrine tumors and actively collaborates in developing the Translational Research and Early Drug Development Unit.
He founded the Spanish Group for Research on Orphan and Uncommon Tumors (GETHI) and serves on the Directory Board of the Spanish Task Force Group for NETs (GETNE). Dr. Grande edits several international journals and has participated in recent neuroendocrine tumor trials that led to the approval of new drugs in this field.